Custom Recombinant Protein Production Services Market Analysis & Forecast: 2026-2033

Custom Recombinant Protein Production Services Market is estimated to be valued at USD 6.80 Bn in 2026 and is expected to reach USD 14.76 Bn in 2033, exhibiting a compound annual growth rate (CAGR) of 11.7% from 2026 to 2033.

Analysts’ Views on Global Custom Recombinant Protein Production Services Market:

Rising funding and investment activities in the field of biotechnology are expected to drive growth of the custom recombinant protein production services market over the forecast period. For instance, On September 08, 2021, Aviva Systems Biology, a Biotechnology company, has announced the launch of its new Protein on Demand semi-custom recombinant protein portfolio for life scientists conducting basic research and preclinical studies.  The Protein on Demand portfolio of over 300,000 proteins enables rapid access to small- to mid-scale production of customized proteins for research teams that struggle to find off-the-shelf solutions or find they do not meet the large-scale production requirements of custom protein expression suppliers.

Figure 1. Global Custom Recombinant Protein Production Services Market Share (%), By Expression System, 2026

To learn more about this report, Download Free Sample

Global Custom Recombinant Protein Production Services Market– Drivers

• Increasing prevalence of diseases such as diabetes, cancer, heart disorders: Recombinant proteins include recombinant hormones, growth factors, interferons, interleukins, blood clotting factors, tumor necrosis factors, thrombolytic drugs, and enzymes for treating major diseases such as diabetes, dwarfism, congestive heart failure, myocardial infarction, cerebral apoplexy, neutropenia, multiple sclerosis, thrombocytopenia, hepatitis, anemia, Crohn’s disease, rheumatoid arthritis, asthma, and cancer, which is expected to drive market growth over the forecast period. Moreover, recombinant proteins are used for the development of vaccines, which can help treat and prevent autoimmune diseases such as rheumatoid arthritis and inflammatory bowel diseases (IBD), Thus, the increasing prevalence of such diseases is expected to drive market growth. For instance, according to the data provided by Breastcancer.org, is an education and support lifeline for millions of people affected by breast cancer in March 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive (in situ) breast cancer.
• Increasing research and development activities for the development of recombinant protein-based products by the key players in the market: Recombinant proteins help to understand the basic and fundamental principles of an organism. They are used to identify and locate the position of the protein encoded by a specific gene and to identify the function of other genes in various cellular activities such as cell signaling, growth, metabolism, replication and death, transcription, translation, and protein modification.

Figure 2. Global Custom Recombinant Protein Production Services Market Share (%), By Region, 2026

To learn more about this report, Download Free Sample

Global Custom Recombinant Protein Production Services Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global custom recombinant protein production services market over the forecast period. North America is estimated to hold 33.5% of the market share in 2026. The increasing adoption of inorganic strategies such as acquisitions and partnerships for the development of recombinant proteins by the key players in the market is expected to act as an opportunity for market growth over the forecast period. For instance, in August 2022, Orthofix US LLC, a medical device company, announced a strategic partnership agreement with CGbio, a developer of innovative, synthetic bone grafts for spine, orthopedic, trauma, and dental applications. As a part of this agreement, the two companies will work together for the clinical development and commercialization of Novosis recombinant human bone morphogenetic protein-2 (rhBMP-2) bone growth materials and other future tissue regenerative solutions for the Canadian and U.S. markets.

For instance, in December 2021, the Ministry of Health and Prevention (MoHAP) U.A.E. approved the emergency use of Sinopharm CNBG's (China National Biotec Group) new recombinant protein vaccine, following the strict monitoring and evaluation of the data of the study conducted in the U.A.E. The ministry affirmed that the emergency use of the new vaccine is in full compliance with the regulations and laws for a faster review of licensing procedures.

Global Custom Recombinant Protein Production Services Market Segmentation:

The global custom recombinant protein production services market report is segmented by expression system, by end user, and by region.

• By expression system, the market is segmented into mammalian, bacteria, insect, yeast, and others. Out of which, mammalian is expected to hold a dominant position in the global custom recombinant protein production services market during the forecast period, and this is attributed to increasing approvals by regulatory authorities.
• By end user, the market is segmented into research institutes, biotechnology and pharmaceutical companies, contract research organizations, and others. Out of which, research institutes are expected to dominate the market over the forecast period, and this is attributed to the increasing establishment of new drug discovery institutes.
• Among all the segments, mammalian segment is expected to dominate the market over the forecast period, and this is attributed to the developments of the new drug discovery institute.

Global Custom Recombinant Protein Production Services Market- Cross Sectional Analysis:

Research institutes in the north america region are focused on the increasing establishment of new drug discovery institute, which are expected to drive market growth in the North America region. For instance, in November 2020, The University of Houston established the Drug Discovery Institute (DDI) with the goal of integrating new technologies such as artificial intelligence to streamline and modernize the drug discovery process. With an emphasis on multi-disciplinary collaborations to include the Texas Medical Center, DDI is focused on physical sciences to develop novel drugs for unmet medical needs, thus defining a new paradigm in academic drug discovery.

Global Custom Recombinant Protein Production Services Market: Key Developments

In July 2021, Atlas Antibodies, a provider of research antibodies based in Stockholm, Sweden, announced the acquisition of Evitria, a Biotechnology company. This transformative acquisition brings together a leading provider of highly validated research antibodies and a front-runner in the field of custom recombinant antibody expression.

In September 2021, Aviva Systems Biology, a company providing antibodies, immunoassay kits, and recombinant proteins for life science research, announced the launch of its new Protein on Demand semi-custom recombinant protein portfolio for life scientists conducting basic research and preclinical studies. The Protein on Demand portfolio of over 300,000 proteins allows rapid access to small- to mid-scale production of customized proteins for research teams.

Global Custom Recombinant Protein Production Services Market: Key Trends

• Increasing inorganic activities such as acquisitions and collaborations: The market players are focused on adopting strategies such as acquisitions and collaborations to gain a strong foothold in the global market. For instance, in December 2021, Thermo Fischer Scientific Inc., a Biotechnology company acquired PeproTech, Inc., which is a developer and manufacturer of recombinant proteins. This acquisition will help Thermo Fischer Scientific Inc. strengthen its recombinant protein portfolio.

Global Custom Recombinant Protein Production Services Market: Restraint

• Complex manufacturing process of recombinant proteins: Recombinant protein production and manufacturing is a complex process, which may act as a restraint on market growth. The recombinant protein manufacturing process is complex and requires higher protein expression, purification, and processing. Moreover, each product requires standardization for large-scale production and purification. As only large-scale production can fulfill the growing demand, thus, it should be cost-effective. Use of recombinant DNA technology for large-scale production of proteins requires a lot of time, labor, and resources. The over-expression and aggregation of the target protein might cause physiological changes in the host cells, thereby causing protein degradation and the production of proteins by the host proteases. Also, for therapeutic purposes, proper modifications and refolding of recombinant proteins are required after purification.  This requires development of new technologies for replacement of Complex manufacturing process of recombinant proteins

Global Custom Recombinant Protein Production Services Market - Key Players

Major players operating in the global custom recombinant protein production services market include GenScript Biotech Corporation, SignalChem Biotech Inc., Crown Bioscience, Inc., BPS Bioscience Inc., Novoprotein, Applied Biological Materials (abm) Inc., Eurofins Pharma Discovery Services, Abgent (WuXi AppTec Company), OriGene Technologies, Inc., Kempbio, Inc., Trenzyme GmbH, Sino Biological Inc., Aragen Bioscience, a GVKBIO Company, LakePharma, Inc.,  Inc., Proteos Inc., Icosagen AS, Novus Biological LLC, Proteogenix, Premas Biotech, ATUM, and Aldevron.

*Definition: Protein expression and purification play a central role in biochemistry. Recombinant proteins can be expressed using prokaryotic systems (E. coli and Bacillus subtilis), eukaryotic systems (yeast, insect cells, mammalian cells), or in vitro systems. A number of new strains, vectors, and tags have been developed in recent years to overcome the limitations of recombinant protein system, such as codon distortion, inclusion body formation, toxicity, protein inactivity, mRNA instability, and lack of post-translational modifications.